CBP-501
Also known as: CanBas-501, CBP-501, CBP501
Source CBP-501 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
CBP‑501 is a synthetic peptide under clinical investigation as an adjuvant to platinum‑based chemotherapy, aiming to increase tumor cell apoptosis and overcome drug resistance.
Mechanism of Action
Binds cyclophilin A, inhibiting DNA‑PK mediated DNA repair and modulating tumor microenvironment, thereby sensitizing cells to DNA‑damaging chemotherapy agents.
Routes of Administration
Goals & Uses
- Sensitization to cisplatin chemotherapyOncology / ChemosensitizationModerate
- Immunogenic cell death inductionOncology / Immuno OncologyLow
- overcome drug resistanceOncologyModerate
- Treatment of malignant pleural mesotheliomaOncology / Solid TumorModerate
- G2/M checkpoint abrogation in cancer cellsOncology / Cell Cycle ModulationModerate
- enhance chemotherapy efficacyOncologyModerate
Contraindications
- Severe hepatic impairmentOrganModerateLiver function concerns
- Severe renal impairmentOrganHighKidney function concerns
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Severe hypersensitivity to CBP-501 or excipientsAllergy / HypersensitivityHigh
Adverse Effects
- Neurotoxicity / peripheral neuropathyNeurologicalUncommon
- Infusion‑related reactionsGeneralUncommon
- Nausea and vomitingGastrointestinalCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- FatigueGeneralCommonLow energy or tiredness
- MyelosuppressionHematologicCommon
- Infusion-related reactionsHypersensitivityUncommon
- NephrotoxicityRenalUncommon
Drug Interactions
- CarboplatinModerate
- PemetrexedModerate
- CisplatinModerate
- Nephrotoxic agentsHigh
Population Constraints
- Patients with pre-existing renal impairmentOrgan FunctionRelative
- Pediatric patientsAgeRelative
- Pregnant or breastfeeding womenReproductiveAbsolute
Regulatory Status
- European UnionInvestigationalEarly‑phase studies pending.
- United StatesInvestigationalPhase I/II clinical trials ongoing.
- United KingdomUnknownNo MHRA approval known; status not clearly documented in public sources.
CBP-501 has not received FDA, EMA, or any other regulatory approval. It has been evaluated in Phase I and Phase II clinical trials in the United States and Japan, primarily in combination with cisplatin.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is CBP-501?
CBP‑501 is a synthetic peptide under clinical investigation as an adjuvant to platinum‑based chemotherapy, aiming to increase tumor cell apoptosis and overcome drug resistance.
What is CBP-501 used for?
CBP-501 is educationally associated with: Sensitization to cisplatin chemotherapy, Immunogenic cell death induction, overcome drug resistance, Treatment of malignant pleural mesothelioma, G2/M checkpoint abrogation in cancer cells, enhance chemotherapy efficacy. Educational only — not medical advice.
How is CBP-501 administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of CBP-501?
Reported adverse effects include: Neurotoxicity / peripheral neuropathy, Infusion‑related reactions, Nausea and vomiting, Nausea, Fatigue, Myelosuppression, Infusion-related reactions, Nephrotoxicity. This list is not exhaustive — consult a qualified clinician.
Who should avoid CBP-501?
Recorded contraindications: Severe hepatic impairment, Severe renal impairment, Pregnancy, Severe hypersensitivity to CBP-501 or excipients. Consult a qualified clinician before use.